Capital Access Window - Ondine Biomedical Inc.

Summary by AI BETAClose X

Ondine Biomedical Inc. has requested a temporary suspension of trading for its common shares on AIM, effective from 7:30 am on September 30, 2026, pending an announcement. This suspension is part of a Capital Access Window, indicating the company is likely preparing to disclose significant financial or strategic news that could impact its share price.

Disclaimer*

AIM
30 September 2026
 

NOTICE

 

30/09/2026 7:30am

 

AIM CAPITAL ACCESS WINDOW

 

ONDINE BIOMEDICAL INC.

 

At the request of the Company trading on AIM for the under-mentioned securities has been temporarily suspended pursuant to a Capital Access Window from 30/09/2026 7:30am, pending an announcement.

 

COMMON SHARES OF NO PAR VALUE, FULLY PAID (CDI)

(BNZGQK5) (CA68234M2058)

 

If you have any queries relating to the above, please contact the Company's nominated adviser on +44 (0)20 7409 3494.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Ondine Biomedical Inc. NPV (CDI) (OBI)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today